Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.61 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | FLT4 | P35916 | 1/20 | 0.55 |
| ▸ | KDR | P35968 | 1/20 | 0.55 |
| ▸ | FBP1 | P09467 | 5/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.53 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.53 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148204 | 0.85 | CA2 (0.54) | PKMLMNAMAPT | |
| SCHEMBL6927818 | 0.83 | PGR (0.65) | PGRFLT1FLT4KDRFBP1 | |
| SCHEMBL10665074 | 0.80 | TSHR (0.57) | PGRFLT1FLT4KDRLMNA | |
| SCHEMBL2371346 | 0.80 | PGR (0.61) | PGRFLT1FLT4KDRFBP1 | |
| SCHEMBL2371349 | 0.80 | LMNA (0.61) | PGRFBP1PKMLMNAMAPT | |
| SCHEMBL11101389 | 0.79 | PTGES2 (0.50) | FLT1FLT4KDR | |
| SCHEMBL138127 | 0.79 | KMT2A (0.58) | PKMLMNAMAPT | |
| SCHEMBL10531636 | 0.78 | PGR (0.54) | PGRFLT1FLT4KDRFBP1 | |
| SCHEMBL11406378 | 0.78 | LMNA (0.63) | PKMLMNATDP1 | |
| SCHEMBL426188 | 0.77 | PGR (0.57) | PGRFLT1FLT4KDRFBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119569658-A | Sulfonyl pyridazinone compound and preparation method and application thereof | 华南师范大学 | 2025-03-07 | — | — | CN | disclosed |
| CN-118184582-A | 4-Seleno-1-benzenesulfonyl pyrazole compound and electrochemical synthesis method and application thereof | 延安大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-113981477-B | Method for preparing pyridazine compound by one-pot two-step electrooxidation cyclization | 南京先进生物材料与过程装备研究院有限公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-114736147-A | Alkene nitrile compound cyclization/hydrolysis reaction method started by sulfonyl free radical in aqueous phase medium | 湖南警察学院 | 2022-07-12 | — | — | CN | disclosed |
| CN-113214129-B | Method for iodination/sulfonylation reaction of 1, 6-diene compound initiated by sulfonyl free radical | 怀化学院 | 2022-06-24 | — | — | CN | disclosed |
| CN-113981477-A | Method for preparing pyridazine compound by one-pot two-step electrooxidation cyclization | 南京先进生物材料与过程装备研究院有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113214129-A | Method for iodination/sulfonylation reaction of 1, 6-diene compound initiated by sulfonyl free radical | 怀化学院 | 2021-08-06 | — | — | CN | disclosed |
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | PGR 4727/4885FLT1 106/4885FLT4 135/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | PGR 4727/4885FLT1 106/4885FLT4 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.